

ASX Announcement

17 November 2017

ViewnVivo installed for evaluation at Stanford University

Highlights:

- **Optiscan's ViewnVivo technology has been installed and is being evaluated at Stanford University in the USA.**
- **Stanford University is one of the world's leading research universities, located in California's Bay Area.**
- **Stanford has chosen to evaluate the ViewnVivo after assessing other microscopic imaging technologies and modalities capable of real-time *in vivo* imaging for preclinical research.**
- **ViewnVivo's flexibility enables *in vivo* imaging not possible with any other current techniques.**
- **Successful evaluation could lead to a potential sale to the University and Optiscan's distribution partner is currently progressing discussions on this matter.**

Optiscan Imaging Limited (ASX:OIL; "Optiscan" or "The Company") is pleased to announce that its innovative ViewnVivo system has been installed for evaluation at Stanford University in the US.

ViewnVivo is Optiscan's endomicroscope system for Preclinical Research that promises to revolutionise microscopic biological imaging. It allows preclinical researchers to obtain cellular and sub-cellular images from living tissue in a living animal (*in vivo*) in real time. It also provides greater control and flexibility - as the researcher can take the imaging to the model rather than adapt the model for imaging - and provides images of significantly higher resolution compared to other existing endomicroscope technologies.

Stanford University is one of the world's leading research universities, located in California's Bay Area. It currently has 7,032 undergraduates and 9,304 graduates, while its research budget is \$US1.6 billion. The University currently has more than 6,000 externally sponsored research projects.

The University selected the ViewnVivo system for evaluation after seeing the system in action at the World Molecular Imaging Congress (WIMC) in Philadelphia in September 2017. It is using ViewnVivo to understand the complexities of biological systems *in vivo* through the use of specific fluorescent dyes.

A successful evaluation, being conducted under agreed success criteria, could lead to a potential sale to the University and Optiscan's exclusive North America distribution partner is currently progressing discussions on this matter.

"The installation, demonstration and evaluation of ViewnVivo at Stanford shows the increasing acceptance of our innovative system by the global Preclinical Research community. We are honoured that a University of Stanford's calibre has selected our platform, particularly as they are very aware of other existing microscopic imaging technologies. This is a significant validation of the ViewnVivo offering," said Optiscan Chief Executive Officer Archie Fraser.

-ENDS-

Corporate Enquiries:

Archie Fraser
Chief Executive Officer
Optiscan Imaging Limited
E: afraser@optiscan.com
P: +61 3 9538 3377

Media Enquiries:

Ruth Thomas
Media + Capital Partners
E: ruth.thomas@mcpartners.com.au
M: 0413 456 491

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes and is now a global leader in the development and application of microscopic imaging technologies for Preclinical Research in science and life sciences as well as medical markets, such as neurosurgery. With the high cost of curative medicine, an opportunity exists for Optiscan's technology to be used globally to reduce costs and be used as a key tool for the early detection of disease, the effective treatment of disease and the improvement of treatment outcomes.